Trial Profile
Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cabazitaxel; Carboplatin; Docetaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 28 Sep 2023 Status changed from active, no longer recruiting to completed.
- 22 May 2023 Planned End Date changed from 31 Mar 2024 to 31 Jul 2024.
- 22 May 2023 Planned primary completion date changed from 31 Mar 2024 to 31 Jul 2024.